Protein / target

Deoxyribonuclease-1

Encoded byDNASE1P24855Homo sapiensSwiss-Prot

UniProt: P24855 Ensembl: ENSG00000213918 HGNC: HGNC:2956 NCBI Gene: 1773

Antibody-tractable

Druggability

UniProt loc high conf

Research papers

Protein at a glance

Biological role

Deoxyribonuclease I

Strongest disease association

Lupus Erythematosus, Systemic

Via encoding gene DNASE1 · Genetic evidence · score 0.58

Research activity

Emerging research

3 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Serum endocuclease secreted into body fluids by a wide variety of exocrine and endocrine organs.

View complete UniProt function annotation

Serum endocuclease secreted into body fluids by a wide variety of exocrine and endocrine organs (PubMed:11241278, PubMed:2251263, PubMed:2277032). Expressed by non-hematopoietic tissues and preferentially cleaves protein-free DNA (By similarity). Among other functions, seems to be involved in cell death by apoptosis (PubMed:11241278). Binds specifically to G-actin and blocks actin polymerization (By similarity). Together with DNASE1L3, plays a key role in degrading neutrophil extracellular traps (NETs) (By similarity). NETs are mainly composed of DNA fibers and are released by neutrophils to bind pathogens during inflammation (By similarity). Degradation of intravascular NETs by DNASE1 and DNASE1L3 is required to prevent formation of clots that obstruct blood vessels and cause organ damage following inflammation (By similarity)

Subcellular location

SecretedZymogen granuleNucleus envelope

Domains and Gene Ontology detail (13)

Gene Ontology

Cextracellular exosome
Cextracellular region
Cnuclear envelope
Cnucleus
Czymogen granule
Factin binding
Fdeoxyribonuclease I activity
FDNA binding
Papoptotic process
PDNA catabolic process
Pneutrophil activation involved in immune response
Pregulation of acute inflammatory response

282 aa · 31 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingGO

View supporting evidence

Immune signalling

·neutrophil activation involved in immune response
·regulation of acute inflammatory response

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene DNASE1

Gene-level evidence surfaced through the gene DNASE1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Lupus Erythematosus, Systemic

0.67Moderately supported

Genetic evidence dominant · Open Targets 0.47

Diabetes Mellitus, Type 2

0.58Moderately supported

Genetic evidence dominant · Open Targets 0.35

Atrial Fibrillation

0.55Moderately supported

Genetic evidence dominant · Open Targets 0.33

HER2 positive breast carcinoma

0.20Preliminary

Genetic evidence dominant · Open Targets 0.12

Neurodegenerative Diseases

0.14Preliminary

Pathway evidence dominant · Open Targets 0.21 · no direct causal or clinical evidence

View evidence synthesis (5)

Lupus Erythematosus, SystemicModerately supported

0.67

agreement 0.55–0.79

Genetic74%Literature13%Animal model13%Genetic literaturedup

Open Targets aggregate 0.47 · 3 independent evidence families · 1 not counted as duplicate

Diabetes Mellitus, Type 2Moderately supported

0.58

agreement 0.44–0.72

Genetic92%Literature8%

Open Targets aggregate 0.35 · 2 independent evidence families

Atrial FibrillationModerately supported

0.55

agreement 0.43–0.67

Genetic100%

Open Targets aggregate 0.33 · 1 independent evidence family

HER2 positive breast carcinomaPreliminary

0.20

agreement 0.07–0.32

Genetic100%

Open Targets aggregate 0.12 · 1 independent evidence family

Neurodegenerative DiseasesPreliminary

0.14

agreement 0.00–0.36

Pathway100%

Open Targets aggregate 0.21 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Lupus Erythematosus, Systemic0.47

Diabetes Mellitus, Type 20.35

Atrial Fibrillation0.33

Neurodegenerative Diseases0.21

HER2 positive breast carcinoma0.12

Tractability

Antibodies — Emerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (small molecule binder) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)